Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.

NCT01805557 is registered in ClinicalTrials.gov with Fondazione Italiana Linfomi - ETS as lead sponsor.

NCT NCT01805557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01805557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.
Lead sponsor
Fondazione Italiana Linfomi - ETS
Phase
Phase 2/3
Overall status
Completed
Start date
February 4, 2013
Completion date
November 20, 2020
Enrollment
108 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma recurrent, diffuse large b-cell lymphoma refractory